The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

被引：18

作者：

Wei, Qing ^{[1
,2
,3
]}

Li, Peijing ^{[2
,4
]}

Yang, Teng ^{[2
,5
]}

Zhu, Jiayu ^{[6
]}

Sun, Lu ^{[2
,7
]}

Zhang, Ziwen ^{[1
,2
]}

Wang, Lu ^{[8
]}

Tian, Xuefei ^{[2
,9
,10
]}

Chen, Jiahui ^{[2
,3
,11
]}

Hu, Can ^{[2
,3
,11
]}

Xue, Junli ^{[12
]}

Ma, Letao ^{[2
,5
]}

Shimura, Takaya ^{[13
]}

Fang, Jianmin ^{[14
]}

Ying, Jieer ^{[1
,2
,3
]}

Guo, Peng ^{[2
,3
]}

Cheng, Xiangdong ^{[2
,3
,11
]}

机构：

[1] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[2] Chinese Acad Sci, Hangzhou Inst Med HIM, Hangzhou, Peoples R China

[3] Upper Gastrointestinal Canc Zhejiang Prov, Key Lab Prevent Diag & Therapy, Hangzhou, Peoples R China

[4] Zhejiang Canc Hosp, Dept Radiat Oncol, Key Lab Head & Neck Canc Translat Res Zhejiang Pro, Hangzhou, Zhejiang, Peoples R China

[5] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou, Peoples R China

[6] Zhejiang Chinese Med Univ, Hangzhou, Peoples R China

[7] Zhejiang Canc Hosp, Dept Gynecol Oncol, Hangzhou, Peoples R China

[8] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China

[9] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China

[10] Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Coll Mol Med, Hangzhou, Peoples R China

[11] Zhejiang Canc Hosp, Dept Gastr Surg, Hangzhou, Peoples R China

[12] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China

[13] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Japan

[14] Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2024年 / 17卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Antibody-drug conjugate; Solid tumor; Combination therapy; Immunotherapy; Targeted therapy; TRASTUZUMAB EMTANSINE T-DM1; METASTATIC BREAST-CANCER; PLUS PEMBROLIZUMAB PEMBRO; DNA-DAMAGE RESPONSE; DERUXTECAN T-DXD; MIRVETUXIMAB SORAVTANSINE; PATIENTS PTS; SACITUZUMAB GOVITECAN; PLATINUM CHEMOTHERAPY; INELIGIBLE PATIENTS;

D O I：

10.1186/s13045-023-01509-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both preclinical studies and clinical trial settings. Nevertheless, combination therapy does not always guarantee a synergistic or additive effect and may entail overlapping toxicity risks. Therefore, understanding the current status and underlying mechanisms of ADC combination therapy is urgently required. This comprehensive review analyzes existing evidence concerning the additive or synergistic effect of ADCs with other classes of oncology medicines. Here, we discuss the biological mechanisms of different ADC combination therapy strategies, provide prominent examples, and assess their benefits and challenges. Finally, we discuss future opportunities for ADC combination therapy in clinical practice.

引用

下载

页数：32

共 50 条

[1] The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Qing Wei
Peijing Li
Teng Yang
Jiayu Zhu
Lu Sun
Ziwen Zhang
Lu Wang
Xuefei Tian
Jiahui Chen
Can Hu
Junli Xue
Letao Ma
Takaya Shimura
Jianmin Fang
Jieer Ying
Peng Guo
Xiangdong Cheng
Journal of Hematology & Oncology, 17
[2] The Promise of Antibody-Drug Conjugates
Teicher, Beverly A.
Doroshow, James H.
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1847 - 1848
[3] Biomarkers for Antibody-Drug Conjugates in Solid Tumors
Katrini, Jalissa
Boldrini, Laura
Santoro, Celeste
Valenza, Carmine
Trapani, Dario
Curigliano, Giuseppe
MOLECULAR CANCER THERAPEUTICS, 2024, 23 (04) : 436 - 446
[4] Antibody-drug conjugates in solid tumors: a new frontier
Jaime-Casas, Salvador
Barragan-Carrillo, Regina
Tripathi, Abhishek
CURRENT OPINION IN ONCOLOGY, 2024, 36 (05) : 421 - 429
[5] Prospects and progress of antibody-drug conjugates in solid tumor therapies
Govindan, Serengulam V.
Sharkey, Robert M.
Goldenberg, David M.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (07) : 883 - 893
[6] Antibody-drug conjugates in solid tumors: a look into novel targets
Criscitiello, Carmen
Morganti, Stefania
Curigliano, Giuseppe
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[7] Antibody-Drug Conjugates Challenges and Trends
Rohrer, Thomas
Genetic Engineering and Biotechnology News, 2024, 44 (03):
[8] Antibody-drug conjugates in solid tumors; new strategy for cancer therapy
Takakura, Toshiaki
Shimizu, Toshio
Yamamoto, Nobuyuki
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (08) : 837 - 846
[9] Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors
Nelson, Blessie Elizabeth
Meric-Bernstam, Funda
ANNUAL REVIEW OF MEDICINE, 2024, 75 : 31 - 48
[10] Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, John M.
Morris, Charles Q.
ADVANCES IN THERAPY, 2017, 34 (05) : 1015 - 1035

← 1 2 3 4 5 →